Related Experiment Video
Updated: May 8, 2026
Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic
Mahmoud A El Hassab1, Wagdy M Eldehna2,3, Ghaneya S Hassan4,5
1Department of Medicinal Chemistry, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, Ras Sudr, 46612, Egypt. mahmoud65582@pharm.tanta.edu.eg.
Abstract:
Presently, humanity is confronted with a range of diseases that have high death rates, especially those linked to cancerous growths. Several enzymes and proteins have been discovered as highly attractive targets for cancer treatment. The PARP family consists of 17 members and plays a crucial role in repairing DNA damage, which enables the survival of cancer cells. PARP-1 and, to a lesser extent, PARP-2 display above 90% activity in response to DNA damage, thereby distinguishing them apart from other members of the PARP family. Elevated levels of PARP-1 were observed in many types of tumor cells, such as breast, lung, ovarian, prostate, and melanomas. In an attempt to provide a future guide for developing selective inhibitors for PARP-1 over PARP-2 to minimize the resulting side effects from PARP-2 inhibitors, we constructed a structure-based virtual screening approach (SBVS). Firstly. A 3D pharmacophore was constructed based on the interaction of the selective inhibitor compound IV. After that, a database of nearly 450,000 phthalimide-containing inhibitors was screened through the validated pharmacophore, and 165 compounds were retrieved. The retrieved compounds were docked into the active site of PARP-1 where only 5 compounds MWGS-1-5 achieved a favorable docking score than the reference IV (-16.8 Kcal/mol). Redocking of the five compounds should have excellent selectivity for PARP-1 over PARP-2, especially compound MWGS-1. Further endorsement via molecular dynamics has proven higher affinity and selectivity for MWGS-1 towards PARP-1 over PARP-2, in which PARP-1- MWGS-1 and PARP-1- MWGS-1 achieved RMSD values of 1.42 and 2.8 Å, respectively.
Insights
Researchers developed a structure-based virtual screening method to identify selective Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. Compound MWGS-1 demonstrated high affinity and selectivity for PARP-1 over PARP-2, offering potential for targeted cancer therapies with fewer side effects.
Area of Science:
- Biochemistry and Molecular Biology
- Computational Chemistry
- Oncology
Background:
- Cancer cells rely on DNA repair mechanisms, including the Poly (ADP-ribose) polymerase (PARP) family, for survival.
- PARP-1 and PARP-2 are key enzymes in DNA damage repair, with elevated PARP-1 levels found in various cancers.
- Developing selective PARP-1 inhibitors is crucial to minimize side effects associated with PARP-2 inhibition.
Purpose of the Study:
- To design and validate a structure-based virtual screening (SBVS) approach for identifying selective PARP-1 inhibitors.
- To discover novel compounds with high affinity and selectivity for PARP-1 over PARP-2.
- To provide a foundation for developing targeted cancer therapeutics with reduced adverse effects.
Main Methods:
- Construction of a 3D pharmacophore model based on a known selective inhibitor.
- Screening a large database of phthalimide-containing compounds against the validated pharmacophore.
- Molecular docking and redocking of retrieved compounds into the PARP-1 active site.
- Molecular dynamics simulations to assess affinity and selectivity of lead compounds.
Main Results:
- A virtual screen of approximately 450,000 compounds yielded 165 potential inhibitors.
- Five compounds (MWGS-1-5) showed favorable docking scores compared to the reference inhibitor.
- Compound MWGS-1 exhibited excellent selectivity for PARP-1 over PARP-2, confirmed by molecular dynamics.
Conclusions:
- The SBVS approach successfully identified selective PARP-1 inhibitors.
- Compound MWGS-1 demonstrates significant potential as a therapeutic agent for PARP-1-targeted cancer treatment.
- Further development of MWGS-1 could lead to more effective and safer cancer therapies.
